

Relationship between methadone therapeutic use and adherence to antiretroviral therapy in Spain

Carlos Parro Torres

Hospital General Universitario Gregorio Marañón Madrid, Spain









Faculty Disclosure

	No, nothing to disclose
Х	Yes, please specify:

Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other (please specify)
Lundbeck	X							
Servier	X							
Janssen	Х							
Esteve	Х							

Index

- I. Introduction: work fundamentals
- II. Objective
- III. Methods
- IV. Results
- V. Discussion
- VI. Conclusions





Heroin Use Disorder and methadone

- Intravenous heroine use has been related to nonadherence to antiretroviral therapy (ART)...
- Opioid substitution treatment (OST) can modify the risk factors related to intravenous drug use impacting adherence (Spire, 2007).
- Patients ceasing injection during OST and abstinent patients exhibit comparable adherence.
- Thus, methadone maintenance therapy has been associated with a greater likelihood of adherence
 (AOR = 1.88, 95% CI: 1.68-2.11) (Azar, 2015).

II. Objective

- The aim of this work is to assess the relationship between methadone substitution treatment and its impact on adherence to antiretroviral therapy (ART)...
- ...among patients attending regularly to HIV consultations...
- ... and receiving ART from the Hospital Pharmacy.





III. Methods

- Case-control cross-sectional study.
- Adherence determined by Hospital Pharmacy pill counting:
 - Case: <90% pills intake (non adherent)
 - Control: > 95% pills intake (adherent)
- Patients in regular follow up in external consultations (at least two visits in the last year).
- Variables collected using an ad hoc questionnaire.





Results

- N= 119.
- Cases (non-adherent): 40
- Controls (adherent): 79.
- 30,3% of the sample had suffered a heroine use disorder during his lifespan.
- 14,3% of the sample was currently receiving methadone in opioid substitution programs.
- No patient received buprenorphine.

Statistical analysis

		Case	Control	χ²
Heroine use history	Yes	20	24	p=0,006
	No	20	55	
Methadone use in	Yes	12	5	P=0,000
general sample	No	38	74	
Methadone among	Yes	12	5	p=0,008
heroine users	No	8	19	



Multivariable model (adjusted analysis)



	В	E.T.	Wald	gl	Sig.	Exp(B)	IC 95%
Age	-0.092	0.044	4.348	1	0.037	0.912	0.837 - 0.995
Gender	-1.346	0.612	4.834	1	0.028	0.260	0.078 - 0.864
Follow up time	0.063	0.041	2.293	1	0.130	1.065	0.982 - 1.154
Number of pills/day	0.515	0.203	6.469	1	0.011	1.674	1.126 – 2.491
Socioeconomic status	1.347	0.581	5.374	1	0.020	3.844	1.231 – 12.001
Alcohol use disorder	1.465	0.673	4.735	1	0.030	4.330	1.157 – 16.206
Cannabis use (active)	-0.646	0.588	1.209	1	0.272	0.524	0.165 – 1.659
Cocaine use (active)	0.380	0.715	0.283	1	0.595	1.463	0.360 - 5.943
Methadone therapy	1.624	0.801	4.112	1	0.043	5.074	1.056 – 24.379
Heroine use (active)	-0.517	1.088	0.226	1	0.635	0.596	0.071 – 5.035

González Álvarez et al. Adicciones, 2017.

Conclusions from our sample

- Methadone substitution therapy was more prevalent among non-adherent patients.
- Among past heroine users, methadone was still more prevalent in non-adherent patients.
- Even after correcting for sociodemographic, treatment and substance use related factors, methadone remains a predictor of nonadherence to ART.





Discussion: Azar et al. 2015. Univariable and multivariable analysis.

Factors associated with ≥ 95% adherence to antiretroviral therapy among 692 illicit drug users.

Characteristic	or 1	95% CI ²	P	AOR 3	95% CI ²	P
Gender (female vs. male)	0.70	0.56 - 0.88	0.002	0.77	0.68 - 0.87	0.038
Age (per 10 years older)	2.04	1.75 – 2.38	<0.001	1.66	1.54 - 1.80	<0.001
Caucasian (yes vs. no)	1.37	1.12 - 1.69	0.002	1.07	0.95 - 1.19	0.571
Heroin injection (yes vs. no) ⁴	0.67	0.58 - 0.78	<0.001	0.76	0.67 - 0.85	0.002
Cocaine injection (yes vs. no) ⁴	0.73	0.63 - 0.85	<0.001	0.74	0.66 - 0.83	0.001
Amphetamine injection (yes vs. no) ⁴	1.14	0.89 - 1.47	0.305			
Crack cocaine smoking (yes vs. no) ⁴	0.95	0.82 - 1.10	0.525			
Methadone maintenance therapy (yes vs. no) ⁴	1.74	1.45 - 2.10	<0.001	1.96	1.75 – 2.19	<0.001
Time since ART initiation (per year increase)	1.08	1.06 - 1.11	<0.001	1.02	0.99 - 1.04	0.090
CD4+ cell count at ART initiation (per 100 cells/mL increase)	0.87	0.83 - 0.92	<0.001	0.88	0.85 - 0.90	<0.001

Is HIV transmission different in Spain? 2015 new cases:

	Modo de transmisión									
Zona geográfica	HS	SH	Hetero	sexual	PI	D	Materno-infantil			
de origen	N	%	N % N % N		%					
España	1286	56,4	480	21,1	78	3,4	0	0,0		
Europa Occidental	74	66,7	14	12,6	2	1,8	0	0,0		
Europa Central-Este	34	33,3	34	33,3	12	11,8	0	0,0		
Latinoamérica	368	67,3	121	22,1	1	0,2	0	0,0		
África Subsahariana	7	3,5	167	83,9	2	1,0	0	0,0		
África del Norte	11	22,0	25	50,0	0	0,0	0	0,0		
Otros	12	42,9	11	39,3	0	0,0	0	0,0		
N.C.	47	42,3	19	17,1	1	0,9	0	0,0		
Total	1839	53,6	871	25,4	96	2,8	0	0,0		



Maybe not nowadays....



Tabla 12: Casos de sida en España por año de diagnóstico, modo de transmisión y sexo. Registro Nacional de Sida. Datos no corregidos por retraso en la notificación.

960

1995

			1995	960	649	443	3850	897	
Año de	HSH	Hete	1996	794	711	469	3544	863	Total
diagnóstico	Н	H	1997	543	586	348	2581	596	I Otal
1981	1	0	1998	452	512	294	1787	455	1
1982 1983	1 4	0							4 14
1984	12	0	1999	387	432	240	1485	349	52
1985	37	2	2000	379	395	265	1277	334	178
1986	87	5	2001	334	402	208	1077	255	499
1987 1988	210 339	23 55							1094 2273
1989	524	110	2002	327	402	242	974	226	3167
1990	583	196	2003	357	397	229	940	208	3937
1991 1992	708 795	253 314	2004	346	351	247	779	194	4576 5093
1993	820	416	2005	292	352	228	694	156	5525
1994 1995	925 960	607 649	2006	301					7494 7195
1996	794	711			317	219	612	139	6758
1997	543	586	2007	302	301	190	541	132	4971
1998 1999	452 387	512 432	2008	324	301	234	434	105	3737 3166
2000	379	395	2009	315	289	204	361	93	2929
2001 2002	334 327	402 402				174	275	-81	2525 2371
2002	357	397	2010	358	240				2313
2004	346	351	2011	333	201	165	251	59	2092
2005 2006	292 301	352 317	2012	334	171	174	207	47	1876 1753
2007	302	301	2013	257	149	115	145	41	1646
2008	324	301							1549
2009 2010	315 358	289 240	2014	223	114	91	101	18	1424 1273
2010	333	201	2015	165	100	71	57	11	1130
2012	334	171	En-jun 2016	25	11	10	12	3	1052
2013 2014	257 223	149 114	N.C.	2	2	2	20	5	818 630
2015	165	100							497
En-jun 2016	25	11	TOTAL*	13156	9366	6285	40560	9464	73
N.C.	2	2	2 20 0	470 500	754 77	222 470	2774	20 7	35
TOTAL*	13156	9366	6285 40560 9464	470 506	754 77	223 176	3774 909	68303 1741	17 85720

HSH=Hombres que mantienen relaciones sexuales con hombres; PID=Personas que se inyectan drogas; N.C.: No consta información; H=Hombres; M=Mujeres. *Por razones técnicas no se han podido incluir los casos de la Comunidad Valenciana a partir de 2014, ni los de la Cataluña en 2015.

...but it used to be



Discussion

- Pandemic HIV infections related to intravenous drug use in Spain (main transmission via) could be related to the diversion between our results and previous data.
- It does not seem plausible that methadone impacts negatively on adherence directly.
- Thus, methadone could be understood as a marker of a patient's profile whose risk for non-adherence is higher, possibly explained by:
 - Socioeconomic factors
 - Active drug use
 - More severe addiction



Thank you!

carlos.parro@hotmail.com



